The "14th Five-Year" Chinese medicine development plan deploys ten key tasks, and the industry development will usher in qualitative changes

On March 29, 2022, the "Notice on Printing and Distributing the "14th Five-Year" Traditional Chinese Medicine Development Plan" was issued
.
It is reported that the "14th Five-Year Plan" for the development of traditional Chinese medicine takes into account the key areas of traditional Chinese medicine development such as medical treatment, scientific research, industry, education, culture, and international cooperation, and proposes ten key tasks.
The plan is more detailed and more maneuverable.

.
The ten key tasks of the "14th Five-Year" TCM development plan include building a high-quality and efficient TCM service system, improving TCM health service capabilities, building a high-quality TCM talent team, and building a high-level TCM heritage protection and technological innovation system, promote the high-quality development of the traditional Chinese medicine industry, develop the traditional Chinese medicine health service industry, promote the prosperity and development of the traditional Chinese medicine culture, accelerate the opening and development of traditional Chinese medicine, deepen the reform of the traditional Chinese medicine field, and strengthen the support and guarantee for the development of traditional Chinese medicine, and have arranged eleven categories, a total of four Fourteen major engineering projects
.
It is also proposed that by 2025, the health service capacity of traditional Chinese medicine will be significantly enhanced, the high-quality development policy and system of traditional Chinese medicine will be further improved, the revitalization and development of traditional Chinese medicine will achieve positive results, and its unique advantages in the construction of a healthy China will be fully utilized
.
Analysts said that the introduction of the "14th Five-Year Plan" for traditional Chinese medicine will promote the development of the industry and usher in a qualitative change
.
Among them, innovative traditional Chinese medicine, traditional Chinese medicine formula granules, brand traditional Chinese medicine, and traditional Chinese medicine services will usher in investment opportunities
.
Taking innovative traditional Chinese medicines as an example, the “14th Five-Year Plan” of traditional Chinese medicine pointed out that the research and development of new traditional Chinese medicines based on ancient classic prescriptions, famous and old traditional Chinese medicine experience prescriptions, and active ingredients or components should be strengthened
.
Support the innovative research and development of Chinese patent medicines for children
.
Promote the establishment of key technical equipment projects for traditional Chinese medicine
.
Driven by policies, innovative Chinese medicines will usher in an outbreak
.
Some innovative Chinese medicine companies will usher in development opportunities
.
The industry recommends paying attention to Yiling Pharmaceutical, Xintian Pharmaceutical, Kangyuan Pharmaceutical, etc.

.
Ruyiling Pharmaceutical is one of the most innovative companies in the Chinese medicine industry in China.
Since its establishment, it has approved 13 new Chinese medicines, covering cardiovascular and cerebrovascular diseases, respiratory diseases, diabetes, tumors, nervous system diseases, and urinary system diseases.
In the fields of multiple clinical and major diseases, a relatively rich product group has been formed
.
It is understood that in recent years, new breakthroughs have been made in the field of innovative Chinese medicine
.
For example, 12 new Chinese medicines will be approved in 2021, more than the sum of the past four years
.
The industry said that in the future, under the promotion of favorable policies, companies with innovative traditional Chinese medicine layouts will stand out
.
In addition to the attention paid to innovative traditional Chinese medicine drugs, analysts said that traditional Chinese medicine formula granules will also become a high-growth track for the traditional Chinese medicine sector
.
Traditional Chinese medicine formula granules refer to granules obtained from single-flavored Chinese medicinal pieces through water extraction, separation, concentration, drying and granulation
.
Compared with traditional Chinese medicine decoction pieces, Chinese medicine formula granules have the advantages of stable raw materials, flexible deployment, and easy portability
.
Data shows that the market size of traditional Chinese medicine formula granules in 2020 is about 53.
3 billion yuan, showing a steady growth trend
.
It is expected that the market of traditional Chinese medicine formula granules is expected to reach a scale of more than 100 billion as the pilot program enters the stage of rising volume and price
.
For traditional Chinese medicine formula granules, analysts suggest paying attention to China Traditional Chinese Medicine, Hongri Pharmaceutical,
etc.
Taking China Traditional Chinese Medicine as an example, the data shows that in 2021, the company's net profit will increase by 16.
2% to 1.
933 billion yuan, of which traditional Chinese medicine formula granule products account for 70% of the total turnover, achieving significant growth
.
The industry believes that in the future, Chinese traditional Chinese medicine is expected to build a complete national supply chain system of traditional Chinese medicine
.
In addition, branded traditional Chinese medicines benefit from consumption upgrades, the demand for medical care grows rapidly, and the demand for branded traditional Chinese medicines continues to grow, and related brands of traditional Chinese medicines will directly benefit
.
As for TCM services, analysts said that the TCM healthcare service industry is large in scale, has a high growth rate, and has yet to see a ceiling.
With the support of policies, it is expected to usher in a golden period of development.

.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.